Tariffs 9731, 9733 and 9735, located on page Q-4 of the Physician’s Manual, may be claimed by approved physicians who use botulinum toxin injections to treat hyperhidrosis. The full tariff descriptions and rules of application are outlined below:
|9731||A series of botulinum toxin injections for axillary hyperhidrosis (bilateral)||$219.70|
|9733||A series of botulinum toxin injections for palmar hyperhidrosis (bilateral)||$323.15|
|9735||A series of botulinum toxin injections for plantar hyperhidrosis (bilateral)||$484.70|
- Botulinum toxin injections are indicated in those cases of hyperhidrosis where conservative measures (e.g. aluminium chloride, iontophoresis, or systemic medications) fail to resolve the problem or where the symptoms of hyperhidrosis are severe enough to give rise to emotional and social, as well as functional problems that impact the patient’s quality of life.
- The treatment shall be administered by a specialist in Dermatology, Plastic Surgery or Neurology with appropriate experience/training in the use of botulinum toxin for these indications, as determined by a consultant group of Doctors Manitoba consisting of representatives from Dermatology, Plastic Surgery and Neurology.
- The treatment includes pre-injection assessment, nerve blocks/local anesthetic, subsequent visits and any further injections within twelve (12) weeks
Billing Notes for Tariffs 9731, 9733 and 9735
Example 1: A series of injections is given for the treatment of axillary hyperhidrosis. The patient’s tolerance is such that injections were only completed on one side. The patient returns to have additional injections on the other side four weeks later. Tariff 9731 may be claimed only once for the initial side and may not be claimed again for the bilateral side.
Example 2: A patient receives a series of bilateral injections for the treatment of palmar hyperhidrosis. Eight weeks later the same patient receives a series of bilateral injections for the treatment of plantar hyperhidrosis. Both tariffs 9733 and 9735 may be claimed in full.
Updated: April 2018